Effects of delay in botulinum toxin treatment on patients with hyperkinetic facial disorders

Main Article Content

Asli Yaman Kula
Zeliha Gunes
Vildan Guzel

Abstract

Aim: Hyperkinetic facial disorders include Benign Essential Blepharospasm (BEB) and Hemifacial Spasm (HFS), which involve involuntary facial muscle contractions. Botulinum toxin (BTX) is essential for relieving symptoms. The Coronavirus-19 (COVID-19) pandemic-related restrictions have led to delays in receiving BTX treatment. This study aims to assess the impact of BTX treatment delays in patients with hyperkinetic facial disorders.


Materials and Methods: This study retrospectively examined the data of 84 patients (68 HFS and 16 BEB) whose BTX appointments were delayed due to COVID-19 restrictions. Patient status was evaluated using Jankovic disability rating scale (JRS) scores, and administered BTX doses were documented and compared before and after lockdown.


Results: After the BTX treatment delay, the median JRS scores significantly increased from 2 before the lockdown to 3 after the lockdown (p<0.001). Furthermore, there was a noticeable increase in the average BTX treatment dose after the lockdown, from 35 units to 37.5 units (p<0.001).


Conclusion: Longer intervals between injections may increase disease severity and the effective BTX  doses in patients with HFS and BEB. The COVID-19 pandemic has highlighted the importance of timely BTX therapy in managing hyperkinetic facial disorders.

Downloads

Download data is not yet available.

Article Details

How to Cite
Yaman Kula, A., Gunes, Z., & Guzel, V. (2023). Effects of delay in botulinum toxin treatment on patients with hyperkinetic facial disorders. Annals of Medical Research, 30(12), 1495–1499. Retrieved from http://annalsmedres.org/index.php/aomr/article/view/4606
Section
Original Articles